Table 1.
Comparison of basic data among patients with different post-SIT PAC levels.
| Parameter | control group(n=144) | indeterminate post-SIT results group (n=282) | PA group(n=118) | P- value |
|---|---|---|---|---|
| Sex(female/male) | 106/38 | 150/132a | 45/73ab | <0.001 |
| Age(years) | 52.20 ± 11.56 | 48.95 ± 10.92a | 49.02 ± 10.04a | 0.004 |
| BMI(kg/m2) | 25.39(23.31,27.48) | 25.91(23.99,28.29) | 26.02(24.03,28.04) | 0.162 |
| Duration of hypertension(years) | 3.00(1.00,7.75) | 2.00(0.23,6.00)a | 3.00(1.00,10.00)b | 0.002 |
| Hypokalemia(%) | 14(9.7) | 41(14.5) | 60(50.8)ab | <0.001 |
| Ever smoker(%) | 16(11.1) | 48(17.0) | 29(24.6)a | 0.017 |
| Diabetes mellitus(%) | 15(10.4) | 35(12.4) | 18(15.3) | 0.499 |
| Systolic BP(mmHg) | 142.77 ± 18.59 | 145.45 ± 17.02 | 151.08 ± 20.80ab | 0.001 |
| Diastolic BP(mmHg) | 86.60 ± 13.82 | 90.45 ± 15.00a | 93.18 ± 14.99a | 0.001 |
| Hypertension stage 3(%) | 10(6.9) | 26(9.2) | 24(20.3)ab | 0.001 |
| Antihypertensive drug classes | 1(0,2) | 1(0,2) | 2(1,3)ab | <0.001 |
| Serum potassium(mmol/L) | 4.01 ± 0.32 | 3.91 ± 0.34a | 3.55 ± 0.49ab | <0.001 |
| Serum sodium,(mmol/L) | 141(140,142) | 141(140,143) | 142(141,144)a | 0.041 |
| CHOL(mmol/L) | 4.48 ± 0.84 | 4.57 ± 0.96 | 4.38 ± 0.97 | 0.167 |
| TG(mmol/L) | 1.39(1.04,1.89) | 1.45(1.07,2.03) | 1.64(1.12,2.43) | 0.053 |
| HDL-C(mmol/L) | 1.21(1.05,1.38) | 1.14(0.99,1.33)a | 1.05(0.93,1.22)ab | <0.001 |
| LDL-C(mmol/L) | 2.57 ± 0.65 | 2.67 ± 0.74 | 2.54 ± 0.78 | 0.383 |
| Dyslipidemia(%) | 55.0(38.2) | 142.0(50.4)a | 58.0(49.2) | 0.036 |
| eGFR( mL/min/1.73m2) | 106.28(100.57,114.28) | 106.52(97.75,114.79) | 107.45(99.32,115.48) | 0.984 |
| Serum creatinine (μmol/L) | 55(50,65) | 64(55,74)a | 65(57,78)a | <0.001 |
| FPG(mmol/L) | 5.09(4.46,5.56) | 5.13(4.52,5.73) | 5.16(4.61,5.84) | 0.177 |
| Glycosylated hemoglobin | 5.50(5.30,5.85) | 5.60(5.30,6.00) | 5.60(5.30,6.10) | 0.456 |
| UACR(mg/g) | 6.00(4.03,11.12) | 7.08(3.48,12.18) | 17.97(5.97,54.19)ab | <0.001 |
| Uric acid(μmol/L) | 307.0(257.0,370.5) | 329.5(267.0,391.5) | 334.0(261.0,405.0) | 0.154 |
| Homocysteine(μmol/L) | 9.90(8.58,12.43) | 11.40(9.50,13.43)a | 11.30(9.60,13.80)a | 0.001 |
| PRA (ng/mL)/h) | 0.2(0.2,0.3) | 0.3(0.2,0.3)a | 0.3(0.2,0.3) | 0.039 |
| PAC (pg/mL) | 134.10(118.10,160.10) | 157.90(131.40,188.15)a | 235.95(182.75,315.90)ab | <0.001 |
| ARR(ng/dl)/(ng/ml per h) | 54.15(40.58,66.25) | 55.35(41.88,73.50) | 87.25(60.41,123.73)ab | <0.001 |
| Pre-SIT PAR (ng/mL)/h) | 0.2(0.2,0.2) | 0.2(0.2,0.2) | 0.2(0.2,0.3) | 0.166 |
| Pre-SIT PAC (pg/mL) | 75.60(65.60,88.05) | 102.90(88.68,121.53)a | 186.60(148.95,249.98)ab | <0.001 |
| Post-SIT PAR (ng/mL)/h) | 0.2(0.2,0.2) | 0.2(0.2,0.2) | 0.2(0.2,0.2)ab | 0.010 |
| Post-SIT PAC (pg/mL) | 42.50(38.73,46.08) | 64.45(58.30,75.00)a | 132.10(113.20,181.88)ab | <0.001 |
a: P < 0.05 vs. control group; b: P < 0.05 vs. indeterminate post-SIT results group; BMI: body mass index; CHOL, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; FPG, fasting blood glucose; UACR, urinary microalbumin/creatinine; PRA, plasma renin activity; PAC, plasma aldosterone concentration; ARR, aldosterone-renin ratio; pre-SIT, pre-saline infusion test; post-SIT, post-saline infusion test.